Introduction
Stem cell transplantation (SCT) followed by donor lymphocyte infusion (DLI) can result in complete cytogenetic responses in myelogenous malignancies, providing strong support for the application of both adoptive and active immunotherapy. Currently, three of the most attractive sources of tumour-specific antigens with a potential therapeutic application to myelogenous leukaemias are the unique fusion-product Bcr/Abl, the overexpressed differentiation-associated molecule WT1 and the Proteinase 3 moiety. The latter is found within the azurophil granules of healthy myeloid cells, is commonly overexpressed by CML cells and has been proposed to play a role in the maintenance of the leukaemic phenotype. 1 Molldrem et al. 2 have previously defined a dominant human leukocyte antigen (HLA)-A2-restricted epitope from this antigen and demonstrated that cytotoxic T lymphocytes (CTL) from healthy donors specific for this peptide were capable of lysing CML, but not healthy, progenitor cells. 3 Moreover, they were able to show the presence of CTL specific for this epitope within CML patients and, furthermore, recipients of SCT or interferon alpha (IFN-a) therapy demonstrated a large increase in the frequency of these CTL, accounting for up to 13% of all circulating CTL, that were functional and could kill autologous CML blasts. This suggests that these CTL may be responsible, at least partly, for the leukaemic cell rejection mediated by these therapies. 4 To identify novel epitopes and to directly confirm the presence of known epitopes from CML-associated antigens, several studies have attempted to isolate and identify MHC ligands from primary CML cells. To date, only one of several studies have been able to identify a natively presented peptide arising from the break-point region of the p210 Bcr/Abl protein, 5 and one peptide from Proteinase 3 6 has also been shown to be naturally presented; although it is unknown if this peptide represents a true epitope. To our knowledge, no such direct evidence is currently available to support the natural processing and presentation of a WT1-derived peptide.
Therefore, we sought naturally processed peptides from known tumour antigens expressed by CML cells and attempted to identify any novel peptides that may have potential as future targets for T-cell-based therapies. This study resulted in the identification of a novel MHC-associated ligand from Proteinase 3, however, no peptides were found from the BCR/ABL fusion protein or the overexpressed differentiation antigen WT1. Peptides derived from several other proteins are known to be overexpressed in haematological malignancies were also identified and may represent prospective targets for immunotherapeutic treatments of CML.
Materials and methods

Patient material
Approximately 1.7 Â 10 11 and 9 Â 10 10 cells were obtained from leukapheresate taken from two CML patients, CML-83 and CML-85, respectively. Patient consent was obtained and local ethics approval was sought for this study. Cell pellets washed three times were flash frozen in liquid nitrogen before being stored at À801C. Aliquots of cells before freezing were kept for flow cytometry and a proportion were cryopreserved in 10% dimethyl sulphoxide (DMSO) and 20% foetal calf serum (FCS) for future studies. Patient material was typed for HLA class I and II alleles. Standard molecular methods were used to establish the HLA-A and -B types, as well as HLA-DR and DQ. The HLA genotype of CML-83 was A*03, A*36, B*1510, B*53. CML-85 was A*0201, A*1101, B*1501 and B*27. Karyotyping of CML-83 showed: 46, XX, ins(4;7)(q21;q22q32), t(7;9;22)(q32;q34;q11) [10] , and for CML-85: 46, XY, t(9;22) (q34;q11) [15] .
Flow cytometric analysis
Patient samples were analysed for their surface expression of MHC class I and II molecules, as well as other surface molecules using indirect immunofluorescent staining as previously described. 7 Affinity purification of MHC class I molecules MHC-peptide complexes from CML-83 and CML-85 were purified as previously described (Flad et al. 8 and Kruger et al., 9 respectively). This method results in the purification of MHC-peptide complexes present on the surface of the cell as well as internal MHC-peptide complexes. Briefly, cell pellets were immersed in ice-cold lysis buffer containing complete protease inhibitor tablets (according to the manufacturer's instructions) (Roche Applied Science, Mannheim, Germany) and homogenised using a Teflon rotor. Following homogenisation, detergent was added to a final concentration of 1%. Lysates were slowly stirred for 3 h at 41C, then centrifuged at 400 g followed by 17 000 g and then sterile filtered using 0.45 mm regenerated-cellulose filters (Millipore, Bedford, MA, USA). Lysate from CML-83 was affinity purified by cycling over a column consisting of 30 mg of the pan-HLA class I-specific antibody (HLA-A, -B, -C) W6/32 antibody bound to NHS (N-hydroxysuccinimide esters) -activated Fast flow Sepharose 4B (Amersham, Uppsala, Sweden) for 6 h, following overnight pre-clearing over a Tris-deactivated Sepharose column. MHC class I from CML-85 was affinity purified by adding 20 mg of W6/32 antibody to the lysate for 1 h at 41C, followed by the antibody-lysate mix being cycled over a Protein-A column. The columns were then washed and the peptides eluted from the antibody-MHC-peptide complexes at pH 2.8. The peptide eluate was concentrated using a 10 kDa membrane (Amicon, Millipore, Bedford, MA, USA) and lyophilised. Aliquots of the purified HLA complexes were obtained and analysed using sodium doduyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Edman sequencing and Westernblot analysis.
Reversed-phase HPLC fractionation and MALDI-TOF analysis
Lyophilised sample was resuspended in pure water/acetronitrile/ trifluoroacetic acid (TFA) (60:40:0.1), vacuum dried until the acetonitril was removed and fractionated by microbore reversed phase-HPLC using a 125 Â 2 mm Grom Saphire C8 column (Grom, Hailfingen, Germany) with an elution gradient of 0-80% system-B (acetonitrile/0.05% TFA (v/v)) over 100 min with a flow rate of 200 ml/min. The eluting peptides were detected at 214 nm and 5 min fractions were collected. The fractions were lyophilised, resolved in 20 ml 0.1% TFA/water (v/v) and frozen at À201C. For MALDI-TOF analysis, 2 ml of the concentrated HPLC-fractions were analysed on a Voyager-DEt STR system (Applied Biosystems, Darmstadt, Germany) in the positive ion reflectron mode. Peptides were cocrystallized with an equal volume of matrix (2,5-dihydroxybenzoic acid (DHB)) using a 1:10 dilution of saturated DHB in 50% (v/v) acetonitrile/water containing 0.1% (v/v) TFA. Spectra were externally calibrated using a standard peptide mixture (des-Arg1-Bradykinin
Online liquid chromatography electrospray ionisation tandem mass spectrometry peptide analysis Online Liquid chromatography electrospray ionisation tandem mass spectrometry (LC-ESI-MS/MS) peptide analysis was conducted as described previously. 9 Peptide MS fragmentation data were analysed using the Mass Lynx software (Waters). Sequest output files were generated for each peptide and screened using an in-house SEQUEST database (ThermoFinnigan, Thermo Electron Corp., Waltham, MA, USA). Peptide sequences that could not be identified with this method were sequenced manually in combination with the Mascot on-line database (www.matrixscience.com). Peptide sequences were only accepted if the origin of every major ion-peak seen within the fragmentation spectra could be explained. Peptides that were deemed of special interest were synthesised using standard f-moc chemistry and the fragmentation spectra of these compared with that obtained from the patient sample.
Results
Phenotypic analysis of the leukapheresate samples indicated that the blasts from both patients expressed the myeloid markers CD13 and CD15, the early myeloid markers CD33 and CD38, and were CD34-negative, and furthermore, both patients possessed the CML-hallmark Philadelphia chromosome. Flow cytrometric analysis also demonstrated that the cells expressed moderate levels of surface MHC class I, however, MHC class II surface expression was negative (data not shown).
MHC-associated peptides from known leukaemic antigens
The peptides obtained from LC-MS-MS analysis of the patients in this study were screened for the presence of known epitopes from BCR-ABL, as well as the other well-documented antigens WT1 and Proteinase 3, with an HLA restriction appropriate for these patients. As well as the known HLA-A2-restricted epitopes from WT1 and Proteinase 3, other potential peptides from these antigens predicted in silico using publicly available algorithms (www.syfpeithi.com) were also included in the analysis, where peptides were predicted for several of the relevant HLA-allelic variants for these patients and for which an algorithm was available. To increase the likelihood that, if present, ions from these peptides would be selected by the mass spectrometer for fragmentation analysis, the instrument was set to select only those ions with a mass to charge ratio (m/z) that would equate to the molecular masses of this list of peptides (not shown), and thereby exclude all other ions that may be of higher abundance. Furthermore, ions with a mass within 0.5 Da of those of the known/predicted peptides were selected for analysis. The fragmentation spectra generated from these ions were then manually sequenced for comparison with those of the known/ predicted epitope using the MassLynx software.
Although numerous ions were detected within the analysed samples, with m/z values that would equate to the molecular masses of the known and predicted peptides, none of the fragmentation spectra from these ions could be matched with the expected sequences for those peptides. Therefore, none of the previously described epitopes from the known CMLassociated antigens, or peptides predicted from these antigens, included in our screen could be detected within the MHCligands eluted and analysed from these two fresh CML samples. However, the absence of the HLA-A3-restricted epitope from the e14a2 (b3a2) transcript variant of BCR-ABL in patient CML-83 is explainable by this patient carrying the e13a2 (b2a2) variant (data not shown).
However, a novel peptide that derives from the N-terminus of Proteinase 3 was found within the MHC-peptide eluate of CML-83 (see Table 1 ), and this peptide contained a motif that would support its binding to HLA-B*1510 (highlighted in bold typeface and underlined, in Table 1 ) based upon data contained within the SYFPEITHI database (www.syfpeithi.de). This peptide also represents the highest-scoring predicted peptide when screening Proteinase 3 using the HLA-B*1510 restriction of the SYFPEITHI algorithm. The MS-MS fragmentation spectrum for this peptide is shown in Figure 1b , where all the major ions ( Figure 1a) are labelled or can be accounted for. Moreover, a H R P P S P A L-COOH 100   0  50  200  150  100  250  300  350  400  450  500  550  600  650  700  750  800  850  900   50  200  150  100  250  300  350  400  450  500  550  600  650  700  750  800  850 Isolation of a novel MHC-associated Proteinase 3 peptide AJ Knights et al synthetic peptide representing this suspected novel Proteinase 3 sequence was synthesised and analysed by LC-MS-MS, and as seen in Figure 1c , the fragmentation spectra indicates the correct sequence interpretation for the isolated peptide.
Identification of novel MHC ligands
The vast majority of the peptides identified in this study derive from ubiquitously expressed self-proteins of both cytoplasmic and nuclear origin, although a proportion of peptides were detected that derive from proteins with limited tissue distribution and include numerous proteins originating from cells of haematopoietic origin. These included four peptides derived from members of the platelet glycoprotein family, glycoprotein IV, platelet glycoprotein IIB and platelet glycoprotein IB (alpha chain). An HLA-A2-restricted peptide deriving from the protein ADP-ribosyl cyclase 2 (BST-1) was detected, a protein that is expressed by bone marrow-derived stromal cells as well as abundantly expressed by cells of the myeloid lineage. Several peptides originate from proteins whose expression is restricted primarily to B-lymphocytes, such as the proteins PRELI (the human px19 homologue) and BAM32, a molecule involved Bcell antigen receptor signalling and cell survival. However, there were numerous peptides identified from both patients which derive from proteins known to be overexpressed by certain tumours or from previously described tumour-associated antigens. These peptide sequences are summarised in Table 1 along with known tumour associations and probable HLA restrictions; based upon peptide motifs contained within the SYFPEITHI database. The significance of these proteins are detailed below.
Association of human neutrophil peptides with the HLA-DR molecules of leukaemic blasts
Although both samples tested negative for surface HLA-DR expression, cell lysates from CML-83 were cycled over an affinity column containing the HLA-DR specific antibody L243 and significant quantities of intracellular HLA-DR were obtained, as determined by SDS-PAGE analysis (data not shown). The ligands of the purified HLA-DR molecules were isolated, purified and analysed by LC-MS. Aside from a limited amount of ions with masses that would correspond to MHC class II-associated peptides (Bm/z 1200-2200) (not shown), Figure 2 shows the MS analysis of one HPLC fraction from this eluate that contained two highly-abundant small polypeptides, and based upon the mass of these ions it is most likely that these proteins are human neutrophil peptides (HNPs). The ion masses 3443 and 3372 shown in Figure 2 would indicate the presence of HNP-1 and HNP-2, respectively.
Discussion
Although the Philadelphia chromosome and the resulting BCR/ ABL fusion protein is a characteristic feature of over 95% of CML cells and several peptides arising from the breakpoint region have been described as T-cell epitopes, to date only one of several studies has been able to find direct evidence, that is isolation of the peptide from MHC, that any of these peptides are naturally processed and presented in the context of MHC. 5 Therefore, in this investigation, we aimed to screen the MHCligands obtained from LC-MS-MS analysis of the patients for the presence of known epitopes -with the appropriate HLA restrictions for these patients -from the CML-associated antigen BCR-ABL, as well as peptides from WT1 and Proteinase 3. To broaden the screen to include potentially novel peptides from these antigens, as well as the known HLA-A2-restricted epitopes from WT1 and Proteinase 3, the masses of in silico predicted peptides from these antigens were also included in the analysis; where peptides were able to predicted for the relevant HLAallelic variants for these patients and for which an algorithm was available. However, as described, we failed to detect any of these epitopes within the peptide pools analysed by LC-MS-MS from our patients. Although, as indicated, the absence of the HLA-A3-restricted epitope from the e14a2 (b3a2) transcript variant of BCR-ABL in patient CML-83 is explainable as this patient expresses e13a2 (b2a2). Recently, Posthuma et al. 10 used a similar mass spectrometric approach in an effort to detect a common HLA-A*0301-restricted BCR-ABL b3a2 epitope. 5 However, this group was also unsuccessful and concluded, as we do, that this absence of detection of BCR-ABL epitopes could arise as result of the copy numbers of these peptide within the complex eluted peptide pools falling below the current sensitivity range of the method employed.
This study did, however, result in the identification a novel peptide that derives from Proteinase 3 and based upon known peptide-HLA binding motifs, support its binding to HLA-B*1510. Interestingly, this peptide also represents the highest-scoring predicted peptide when screening the Proteinase 3 protein sequence using the HLA-B*1510 restriction of the SYFPEITHI algorithm. Although the immunogenicity of this peptide still needs to be determined to support its applicability as a vaccine target for HLA-B*1510 positive patients, we feel that these data further support the application of Proteinase 3 as a target in myelogenous leukaemias. It has been estimated that approximately 10 000 peptides may be presented in the context of MHC on a cell, 11 and current technology only allows for the identification of around one hundred at best, and therefore it is assumed, and taking into account the sensitivity of this method, that these peptides most likely represent the most abundant MHC ligands present. Hence, the identification of our novel Proteinase 3 peptide taken in context with the previous HLA-Brestricted Proteinase 3 peptide identified by Papadopoulos et al., 6 would indicate that this protein might frequently result in naturally processed and presented MHC-ligands of a higher copy number per cell. As reported by other groups using this methodology, the vast majority of the peptides identified in this study derive from ubiquitously expressed self-proteins of both cytoplasmic and nuclear origin, although in addition, a fraction of peptides derive from proteins with limited tissue distribution and included numerous proteins originating from cells of haematopoietic origin. Conversely, we were able to identify a number of peptides that originate from proteins that have been described to be either over expressed in certain tumours or that are derived from known tumour-associated antigens.
From CML-83, several peptides were identified from the proliferating cell nuclear antigen (PCNA), known to be upregulated in leukaemic cells and modulated by Bcr/Abl, 12 and furthermore, these peptides were found presented in the context of two different MHC molecules; HLA-A*36 & B*1510. Additional B*1510-associated peptides included peptides from CDC28 protein kinase 1B, apolipoprotein A-1 and MEK kinase 1. All of these genes have been described as being upregulated as a result of neoplastic transformation, with the latter's upregulation directly influenced by the Bcr-Abl oncogene. 13 One potentially interesting peptide was detected that originates from the cytoskeletal-modulating protein, Stathmin (oncoprotein 18), which has also been shown to be overexpressed as a result of Bcr-Abl transformation. 13 This finding was also reported by Hakansson et al., 12 as well as overexpression in a number of other tumour histologies.
14 Moreover, the detection of a humoral response against Stathmin in renal cell carcinoma (RCC) patients would indicate that this protein is immunogenic in other tumors. 15 In addition to the peptide from Stathmin, an MHC ligand was also identified from an additional protein to which a humoral response has been previously detected in tumour patients, Elongation factor 1-alpha 1. This has been identified in a cutaneous T-cell lymphoma (CTCL). 16 The gene has several pseudonyms, including prostate-tumour-inducing gene I (PTI-1), which may result from the fact that multiple copies of this gene have been found on several chromosomes. However, the identification of this protein by SEREX analysis of a CTCL patient (termed tumour antigen HD-CL-08) may again support this antigen as a potential target. The detection of humoral immune responses can be indicative of a broader immune response to a tumour antigen; certainly this has been shown to be true for the cancer-testis antigen NY-ESO-1, 17 where a humoral response correlates with a cellular CD8 þ cellmediated response. Therefore, both of the peptides identified from the two previously described antigens, Stathmin and PTI-1, restricted to HLA-A*11 and -B*1501, respectively, warrant further investigation as potential T-cell epitopes.
From patient CML-85, several peptides were found that originate from proteins belonging to the family of RNA helicases. Numerous proteins belonging to this family have been implicated as having a role in cancer and have been the subject of a recent review. 18 An HLA-A*0201-associated peptide that appeared in high abundance, as seen by LC-MS-MS analysis, derived from the DEAD-box protein P68 (DDX5), which has been described as having several potential roles in tissue and cellular differentiation and was found to be overexpressed at the protein level in colorectal carcinoma. 19 Another HLA-A*0201-associated peptide that may be of interest due to the known expression of the protein originates from DEAD-box protein p54 (also known as the RCK oncogene) that was originally identified in a diffuse large B-cell lymphoma and has been found to be overexpressed in several tumour types. 20 This peptide was also previously identified amongst MHC-ligands isolated from RCC cells by Kruger et al. 9 Preliminary investigations in HLA-A2-positive healthy donors indicate that this peptide is not immunogenic; however, these experiments need to be repeated in a larger cohort of HLA-A2-positive donors.
Initially, we planned experiments to identify the MHC-class II associated peptides expressed on CML blasts, however, both patient samples tested negative for surface MHC class II expression. Conversely, significant quantities of intracellular HLA-DR was obtained when cell lysates from CML-83 were cycled over an HLA-DR affinity column, and thus we were able to analyse the ligands of these purified intracellular molecules by LC-MS. Aside from a limited number of ions with masses that would correspond to MHC class II-associated peptides, analysis of this eluate indicated the presence of two highly abundant small polypeptides, and based upon their mass it is most likely that these proteins are the HNPs HNP-1 and HNP-2, antimicrobial peptides previously described to be associated with MHC class II in CD34-negative CML blasts. 21 In the publication from Halder et al., 21 it is speculated that the HLA-DR-associated HNP-peptides could result from either endogenous processing of the polypeptides or from exogenous cleavage and MHC loading of the secreted polypeptides. However, our results would indicate that the MHC ligands must be processed endogenously as no surface HLA-DR was detected on our samples. The significance of the association between HLA-DR and the human neutrophil peptides is still unclear.
In conclusion, we identified several peptides from proteins that have previously been described as overexpressed or immunogenic in tumours. We also focussed on proteins where the expression of which was upregulated as a result of Bcr/Abl transformation, which warrant further investigation. Although no peptides from either Bcr/Abl or WT1 were identified in this study, this does not necessarily indicate that peptides from these antigens are not present within the MHC-'ligandome' but rather they may be present in a quantity that is below our current level of detection. However, this is the second of only a small number of studies analysing the MHC-ligands of patient CML cells to find and identify a peptide from the antigen Proteinase 3, and this may therefore indicate that peptides from this antigen are among the more abundantly presented of the known leukaemic antigens. These data, taken together with clinical observations involving the presence of functional Proteinase 3 specific CTL in patients' further supports the application of this antigen as a target for immunotherapy in CML.
